Gene:
AKR1B1
aldo-keto reductase family 1, member B1 (aldose reductase)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  ALDR1
Alternate Symbols:  AR
PharmGKB Accession Id: PA24675

Details

Cytogenetic Location: chr7 : q35 - q33
GP mRNA Boundary: chr7 : 134127107 - 134143888
GP Gene Boundary: chr7 : 134124107 - 134153888
Strand: minus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Cyclophosphamide Pathway, Pharmacodynamics
    Model non-tissue-specific cancer cell displaying genes which may be involved in the cyclophosphamide pathway.
  1. Ibuprofen Pathway, Pharmacodynamics
    Stylized cell depicting the mechanism of action of ibuprofen (IBU).
  1. Ifosfamide Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes which may be involved in the ifosfamide pathway.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this gene. To report a pathway, click here.

No related genes are available

Curated Information ?

Publications related to AKR1B1: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer cell. 2002. Yeoh Eng-Juh, et al. PubMed

LinkOuts

NCBI Gene:
231
OMIM:
103880
UCSC Genome Browser:
NM_001628
RefSeq RNA:
NM_001628
RefSeq Protein:
NP_001619
RefSeq DNA:
NT_007933
NT_079596
UniProtKB:
ALDR_HUMAN (P15121)
Ensembl:
ENSG00000085662
GenAtlas:
AKR1B1
GeneCard:
AKR1B1
MutDB:
AKR1B1
ALFRED:
LO024130K
HuGE:
AKR1B1
Comparative Toxicogenomics Database:
231
ModBase:
P15121
HumanCyc Gene:
HS01502
HGNC:
381

Common Searches